TCGA-95-7043-01A-11R-1949-07
— · cohortA4
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA4
- subtype
- cohortA4
- age_years
- 63
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- SPERMATOGENESIS+0.240
- PANCREAS_BETA_CELLS+0.230
- XENOBIOTIC_METABOLISM+0.190
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.150
- ESTROGEN_RESPONSE_EARLY+0.130
- FATTY_ACID_METABOLISM+0.110
- KRAS_SIGNALING_DN+0.110
- ESTROGEN_RESPONSE_LATE+0.090
- BILE_ACID_METABOLISM+0.080
- ANGIOGENESIS+0.060
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.580
- INTERFERON_GAMMA_RESPONSE-0.560
- TNFA_SIGNALING_VIA_NFKB-0.560
- ALLOGRAFT_REJECTION-0.430
- IL6_JAK_STAT3_SIGNALING-0.420
- TGF_BETA_SIGNALING-0.400
- APOPTOSIS-0.390
- INFLAMMATORY_RESPONSE-0.390
- PI3K_AKT_MTOR_SIGNALING-0.390
- HYPOXIA-0.370
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-53-A4EZ-01A-12R-A24X-07 | — | cohortA3 | 0.885 |
| 2 | SRR25617918 | — | B | 0.859 |
| 3 | C3L-03726 | — | cohortA2 | 0.858 |
| 4 | ERR2278863 | — | — | 0.841 |
| 5 | 66326_S124 | — | cohortA1 | 0.839 |
| 6 | SRR33532828 | — | B | 0.838 |
| 7 | TCGA-XF-A8HG-01A-11R-A36F-07 | — | — | 0.835 |
| 8 | SRR8613793 | — | B | 0.829 |
| 9 | SRR33346947 | — | — | 0.823 |
| 10 | MDT-AP-1131 | Med | Medulloblastoma | 0.821 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| SPERMATOGENESIS | 0.240 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.230 | Cobimetinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.190 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.150 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.130 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.110 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.090 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.080 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.060 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.020 | Idelalisib | — uncovered |